NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CTNM

Contineum Therapeutics Inc

Jul 03 • 02:42PM ET

3.88

Dollar change -0.12
Percentage change -3.00	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB GILD AMGN MRNA BMY LLY PFE JNJ

| Held by: VTI VXF VTWO IWC SCHA VTWG VTWV MSSM EBIT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.93	Insider Own	47.82%	Shs Outstand	19.14M	Perf Week	-3.24%
Market Cap	100.39M	Forward P/E	-	EPS next Y	-2.83	Insider Trans	0.00%	Shs Float	13.50M	Perf Month	-18.14%
Enterprise Value	-84.32M	PEG	-	EPS next Q	-0.44	Inst Own	43.16%	Short Float	5.73%	Perf Quarter	-42.77%
Income	-49.83M	P/S	-	EPS this Y	-7.75%	Inst Trans	-4.74%	Short Ratio	5.47	Perf Half Y	-73.19%
Sales	0.00M	P/B	0.54	EPS next Y	-20.52%	ROA	-30.97%	Short Interest	0.77M	Perf YTD	-73.52%
Book/sh	7.14	P/C	0.53	EPS next 5Y	-8.65%	ROE	-91.32%	52W High	21.92 -82.30%	Perf Year	-81.52%
Cash/sh	7.37	P/FCF	-	EPS past 3/5Y	-30.13% -	ROIC	-26.32%	52W Low	3.35 15.82%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.15% 13.17%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-294.54%	Oper. Margin	-	ATR (14)	0.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	21.47	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	45.76	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	21.47	EPS Q/Q	-88.91%	SMA20	-9.32%	Beta	0.78	Target Price	23.71
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-5.88%	Rel Volume	1.02	Prev Close	4.00
Employees	41	LT Debt/Eq	0.02	Earnings	May 14 AMC	SMA200	-62.12%	Avg Volume	141.44K	Price	3.88
IPO	Apr 05, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.73% -	Trades		Volume	143,855	Change	-3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-20-25	Initiated	William Blair	Outperform
Oct-22-24	Initiated	Robert W. Baird	Outperform	$32
Apr-30-24	Initiated	Stifel	Buy	$29
Apr-30-24	Initiated	RBC Capital Mkts	Outperform	$30
Apr-30-24	Initiated	Morgan Stanley	Overweight	$25

Jun-25-25 08:15AM	Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
May-15-25 04:05PM	Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference (Business Wire) -10.91%
May-14-25 04:05PM	Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
Apr-28-25 04:05PM	Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development (Business Wire)
Mar-17-25 04:05PM	Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors (Business Wire) +5.85% +6.09%
04:05PM	Loading…
Mar-12-25 04:05PM	Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum (Business Wire) -5.56%
Mar-06-25 04:05PM	Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones (Business Wire) +5.57% +5.12%
Mar-04-25 04:05PM	Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 (Business Wire) -5.16%
Mar-03-25 04:05PM	Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference (Business Wire) -6.39%
Jan-08-25 04:05PM	Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) (Business Wire)
Jan-06-25 08:00AM	RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors (GlobeNewswire)
Dec-16-24 04:05PM	Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
Nov-25-24 08:05AM	Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference (Business Wire) +9.01%
Nov-18-24 08:05AM	Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain (Business Wire) -8.02%
Nov-13-24 04:05PM	Contineum Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
04:05PM	Loading…
Nov-06-24 04:05PM	Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) +7.60%
Aug-28-24 04:05PM	Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences (Business Wire) -7.00%
Aug-13-24 04:05PM	Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -6.06% +6.21%
Jul-31-24 04:05PM	Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis (Business Wire) -5.33%
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-04-24 04:05PM	Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference (Business Wire)
Jun-03-24 04:05PM	Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary (Business Wire)
May-20-24 04:05PM	Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors (Business Wire)
May-16-24 04:05PM	Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Apr-04-24 09:02PM	Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lorrain Daniel S.	Chief Scientific Officer	Nov 25 '24	Sale	16.02	1,010	16,177	168,562	Nov 27 05:06 PM
Lorrain Daniel S.	Chief Scientific Officer	Nov 18 '24	Sale	16.38	6,190	101,421	169,572	Nov 20 05:07 PM
DANIEL LORRAIN	Officer	Nov 18 '24	Proposed Sale	17.21	26,370	453,828		Nov 18 05:05 PM
Huhn Stephen L.	CMO & Sr VP, Clinical Dev.	Aug 13 '24	Option Exercise	1.01	12,800	12,928	12,800	Aug 14 06:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTNM

Contineum Therapeutics Inc

Upgrade your FINVIZ experience